

Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer

Cell therapy expert to assume responsibility for clinical development and regulatory affairs

Gosselies, Belgium, 6 March 2017, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces the appointment of Miguel Forte, MD, PhD as Chief Medical Officer (CMO).

Dr. Forte has significant regenerative medicine and cell therapy industry experience, most recently as Chief Operating and Medical Officer at TxCell, a French biotechnology company specializing in immune cell therapy, and as Chief Commercialization Officer and Chair of the Commercialization Committee at the International Society of Cellular Therapy (ISCT). With over 20 years' industry experience, Dr. Forte has gained broad expertise in medical and regulatory affairs, ranging from leading early and late stage clinical trials to market authorization and the launch of new biologic products for various indications.

At Bone Therapeutics, Dr. Forte will be responsible for the Company's clinical development strategy and advancing its products to market. He will also play a key role in increasing the visibility of the Company throughout the medical community.

At TxCell, Dr. Forte was instrumental in defining the company's regulatory strategy, design and implementation of clinical studies and completed a positive first-in-man Phase I/II study with an antigen specific T-cell therapy. Prior to TxCell, Dr. Forte held several senior positions in large pharmaceutical companies, including as Vice President, Global Medical Affairs at UCB, and various senior positions at the European Medicines Agency, Bristol-Myers Squibb, Abbott, and Wellcome Laboratories (now part of GSK).

Dr. Forte graduated in Medicine from the University of Lisbon, specializing in infectious diseases. He obtained a PhD in Immunology at the University of Birmingham and received post-graduate training in Health Economics of Pharmaceutical and Medical Technology at Stockholm School of Economics. Dr. Forte is currently Associate Professor in Health Sciences and Pharmacy at the University of Aveiro and the University of Lisbon. Dr. Forte succeeds Prof. Dr. Valerie Gangji, who will focus on her role as Head of the Rheumatology and Physical Medicine Unit at the Erasme University Hospital. Dr. Gangji will remain available to the Company during a transition period to provide advice and support on ongoing clinical programmes.

Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: *"We are delighted to strengthen our clinical development team with the appointment of Dr. Forte. His vast expertise in cell therapy will be a strong asset to our company and will further drive the progress of Bone Therapeutics' innovative pipeline. In addition to his specific experience with cell therapy products, Dr. Forte has extensive experience in interacting with regulatory bodies and establishing strong relationships with investigators and key opinion leaders. We would like to thank Valérie Gangji for her contribution to our company. She pioneered the use of differentiated bone forming cells and her work forms part of the foundation of Bone Therapeutics' bone cell therapy products."*

Commenting on his appointment, Dr. Miguel Forte said: *"I am very excited to be joining Bone Therapeutics, a leading biotechnology company in bone cell therapy products. The Company has an advanced clinical pipeline with promising products in clinical development and I am impressed with its progress to date. I look forward to working with the Bone Therapeutics team to realise the potential of its ground breaking products for the benefits of patients."*

● About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for orthopaedics and bone diseases. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB[®], Bone Therapeutics' autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures. ALLOB[®], its allogeneic "off-the-shelf" bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs for the development of novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at: www.bonetherapeutics.com.

● For further information, please contact:

Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer
Wim Goemaere, Chief Financial Officer

Tel: +32 (0)2 529 59 90

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries:

Consilium Strategic Communications

Amber Fennell, Jessica Hodgson and Hendrik Thys

Tel: +44 (0) 20 3709 5701

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:

NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

Tel: + 33 (0)1 44 71 94 94

bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
